| Target Molecule | Desmopressin (DDAVP) |
| Synonyms | DDAVP, dDAVP, 1-deamino-8-D-arginine vasopressin, Minirin |
| CAS Number | 16679-58-6 (free base); 62288-83-9 (monoacetate), 16789-98-3 (diacetate) |
| Sequence (3-Letter) | Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH₂ (cyclic Mpa1–Cys6 disulfide) |
| Sequence (1-Letter) | (Mpa)YFQNCPrG-NH₂ (Mpa = 3-mercaptopropionyl; r = D-Arg) |
| Molecular Formula | C₄₆H₆₄N₁₄O₁₂S₂ (free base) |
| Molecular Weight | 1069.22 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Directed Disulfide Cyclization |
| Modification Options | N-terminal deamination (Mpa incorporation), D-arginine substitution, intramolecular disulfide bridging, stable isotope labeling (13C, 15N), linear precursor impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Desmopressin (DDAVP, CAS 16679-58-6) is a synthetic cyclic nonapeptide featuring an N-terminal 3-mercaptopropionyl (Mpa) group and a D-Arginine substitution at position 8 (Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH₂). We target this sequence to supply high-purity reference materials and raw materials for diabetes insipidus and hemostasis research.
Incorporating N-terminal Mpa requires specialized coupling conditions since the terminal amino group is absent. Our peptide synthesis platform combines optimized Solid-Phase Peptide Synthesis (SPPS) with directed oxidative folding between Mpa1 and Cys6, ensuring precise ring closure and high monomeric purity.
Yes. We provide specialized peptide modification services for vasopressin analogues. Options include the synthesis of uncyclized linear precursors as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), and L-Arg diastereomer controls.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Desmopressin (CAS 16679-58-6), widely known as DDAVP or Minirin, is a synthetic nonapeptide functioning as a selective vasopressin V2 receptor agonist. Defined by the sequence (Mpa)YFQNCPrG-NH₂ with an intramolecular Mpa1–Cys6 disulfide bridge and D-arginine at position 8, it exhibits enhanced antidiuretic potency and metabolic stability compared to native vasopressin. Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, demonstrating our technical expertise in N-terminal deamination, directed disulfide cyclization, and CDMO manufacturing.
Constructing Desmopressin requires precise integration of a non-standard N-terminal building block (3-mercaptopropionic acid) and a D-enantiomer at position 8. Because Mpa lacks an alpha-amino group, standard terminal coupling methods are inapplicable. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols followed by specialized terminal acylation. By regulating reaction kinetics, we suppress deletion fragments and deliver raw materials with rigorous purity specifications (typically ≥98% or ≥99% via HPLC).
The pharmacological efficacy of Desmopressin relies strictly on the correct formation of the Mpa1–Cys6 disulfide macrocycle. Uncontrolled oxidation can lead to inactive linear forms or polymeric aggregates. Through our peptide modification services, we execute precise oxidative folding under high-dilution conditions and verify disulfide connectivity using high-resolution LC-MS/MS and peptide mapping. We also synthesize linear uncyclized precursors and L-Arg diastereomer impurities as vital reference standards for stability-indicating assays.
Transitioning a modified cyclic nonapeptide from laboratory scale to commercial volume demands robust downstream process engineering. We execute large-scale peptide synthesis for Desmopressin by optimizing continuous-flow oxidation systems and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
